FierceBiotech  Apr 3  Comment 
A few days after a similar announcement from GlaxoSmithKline, Sanofi said it plans to scale up its presence in Africa, looking to invest in marketing and R&D in response to the market's continued growth.
Reuters  Apr 2  Comment 
Sanofi is on the lookout for acquisitions to boost key business units, such as consumer and animal health products, and expects strong growth in the "strategic continent" of Africa, its chief executive told Reuters on Wednesday.
newratings.com  Apr 1  Comment 
PARIS (dpa-AFX) - Sanofi Pasteur, the vaccines division of Sanofi (SNY), announced the U.S. FDA has expanded the approved age indication of Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed; Tdap) for...
StreetInsider.com  Apr 1  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sanofi+SNY%29%2C+Regeneron+%28REGN%29+Reports+Alirocumab+Phase+2+Met+Primary+Endpoint+in+Japanese+Patients/9336530.html for the full story.
FiercePharma  Mar 31  Comment 
Last week, Johnson & Johnson chalked up a Big Pharma first by hiring a chief design officer. This week, the groundbreaker is Sanofi. The job? Chief Patient Officer.
newratings.com  Mar 28  Comment 
PARIS (dpa-AFX) - French drug maker Sanofi (SNYNF.PK, SNY) Monday announced the appointment of Anne Beal to the newly created position of Chief Patient Officer. Beal is a pediatrician and public health specialist. She joins Sanofi from...
StreetInsider.com  Mar 27  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sanofi+%28SNY%29%2C+Regeneron+%28REGN%29+to+Present+Alirocumab+Data+at+ACC+Annual+Session/9321407.html for the full story.
DailyFinance  Mar 26  Comment 
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced the Food and Drug Administration (FDA) approved revised prescribing information for the use of Thyrogen® (thyrotropin alfa for injection) to ...
FierceBiotech  Mar 26  Comment 
After 20 years in the lab and $1.4 billion in R&D costs, Sanofi's in-development dengue fever vaccine is on the verge of regulatory applications, and, despite a few clinical hiccups, the drugmaker told Reuters it believes it has a blockbuster on...
StreetInsider.com  Mar 26  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sanofi%27s+%28SNY%29+Genzyme+Exercises+Right+for+344.5K+Shares+of+Alnylam+%28ALNY%29+/9317478.html for the full story.


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki